These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 24132726)

  • 21. Hormonal therapy for advanced breast cancer.
    Rugo HS
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):273-91. PubMed ID: 17512449
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer.
    McCaig FM; Renshaw L; Williams L; Young O; Murray J; Macaskill EJ; McHugh M; Hannon R; Dixon JM
    Breast Cancer Res Treat; 2010 Feb; 119(3):643-51. PubMed ID: 19941160
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical review: Effect of endocrine therapies on bone in breast cancer patients.
    Santen RJ
    J Clin Endocrinol Metab; 2011 Feb; 96(2):308-19. PubMed ID: 21147884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exemestane for primary prevention of breast cancer in postmenopausal women.
    Zhang Y; Simondsen K; Kolesar JM
    Am J Health Syst Pharm; 2012 Aug; 69(16):1384-8. PubMed ID: 22855103
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Osteoporosis and breast cancer.
    Fontanges E; Fontana A; Delmas P
    Joint Bone Spine; 2004 Mar; 71(2):102-10. PubMed ID: 15116704
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
    Brufsky A
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Breast cancer and osteoporosis.
    Cheung AM; Heisey R; Srighanthan J
    Curr Opin Endocrinol Diabetes Obes; 2013 Dec; 20(6):532-8. PubMed ID: 24468755
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of bisphosphonates in the adjuvant setting for breast cancer.
    Reeder JG; Brufsky AM
    Oncology (Williston Park); 2010 May; 24(6):462-7, 475. PubMed ID: 20568587
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis.
    Hadji P
    Crit Rev Oncol Hematol; 2009 Jan; 69(1):73-82. PubMed ID: 18757208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bone targeted therapies in early breast cancer.
    Tabane K; Vorobiof DA
    Curr Treat Options Oncol; 2011 Dec; 12(4):412-23. PubMed ID: 21887503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of bone health in postmenopausal women on aromatase inhibitors (AIs): a single health care system experience.
    Tremblay D; Patel V; Fifer KM; Caro J; Kolodka O; Mandelli J; Shapiro CL
    Support Care Cancer; 2018 Jan; 26(1):197-202. PubMed ID: 28744736
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Managing aromatase inhibitors in breast cancer survivors: not just for oncologists.
    Files JA; Ko MG; Pruthi S
    Mayo Clin Proc; 2010 Jun; 85(6):560-6; quiz 566. PubMed ID: 20511486
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tolerability of Therapies Recommended for the Treatment of Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer.
    Ohno S
    Clin Breast Cancer; 2016 Aug; 16(4):238-46. PubMed ID: 27151773
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term "protective" effect of aromatase inhibitors on the endometrium of postmenopausal breast cancer patients.
    Markovitch O; Tepper R; Fishman A; Aviram R; Cohen I
    Breast Cancer Res Treat; 2009 Jan; 113(2):321-6. PubMed ID: 18297393
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Screening for osteoporosis after breast cancer: for whom, why and when.
    Trémollieres FA
    Maturitas; 2014 Nov; 79(3):343-8. PubMed ID: 25308162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advances in adjuvant hormonal therapy for postmenopausal women.
    Strasser-Weippl K; Goss PE
    J Clin Oncol; 2005 Mar; 23(8):1751-9. PubMed ID: 15755983
    [No Abstract]   [Full Text] [Related]  

  • 37. Preventing osteoporosis in symptomatic postmenopausal women.
    Gallagher JC; Levine JP
    Menopause; 2011 Jan; 18(1):109-18. PubMed ID: 20661164
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention of osteoporosis after breast cancer.
    Reid DM
    Maturitas; 2009 Sep; 64(1):4-8. PubMed ID: 19709826
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Treatment guideline for breast cancer and SERM-treatment].
    Iwase H; Yamamoto Y; Kawasoe T
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():636-40. PubMed ID: 18159717
    [No Abstract]   [Full Text] [Related]  

  • 40. Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper.
    Rizzoli R; Body JJ; DeCensi A; Reginster JY; Piscitelli P; Brandi ML;
    Osteoporos Int; 2012 Nov; 23(11):2567-76. PubMed ID: 22270857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.